A Multiple Dose Study of MK-5172 in Hepatitis C-Infected Participants (MK-5172-010 AM1)

Inclusion criteria:

• Body Mass Index (BMI) ≥18.5 kg/m² and ≤36.0 kg/m²
• Chronic compensated, genotype 1 HCV infection
• No cirrhosis as confirmed by FibroSure®/Fibro Test®
• No need for anticoagulants, nonsteroidal anti-inflammatory agents, and aspirin for at least fourteen (14) days preceding the initial liver biopsy and continuing throughout the entire study
• Female participants of reproductive potential willing to use 2 medically acceptable forms of contraception for 2 weeks prior to start of treatment through 2 weeks after last study treatment
• Male participants with partners of reproductive potential willing to use 2 medically acceptable forms of contraception from first dose to 90 days after last dose

Exclusion criteria:

• History of stroke, chronic seizures, or major neurological disorder
• Previous treatment with a Direct-Acting Antiviral (DAA)
• Evidence of high grade bridging fibrosis from prior liver biopsy within 3 years of study entry
• Evidence or history of chronic hepatitis not caused by HCV infection including but not limited to non-HCV viral hepatitis, nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, or autoimmune hepatitis
• Clinical or laboratory evidence of cirrhosis or other advanced liver disease
• Decompensated liver disease as indicated by a history of ascites, hepatic encephalopathy, or bleeding esophageal varices
• Diagnosed or suspected of having hepatocellular carcinoma
• Clinically significant abnormality on an electrocardiogram (ECG)
• Co-infection with human immunodeficiency virus (HIV)
• Positive Hepatitis B surface antigen or other evidence of active Hepatitis B infection
• History of gastric bypass surgery, bowel resection or other disorder that may interfere with absorption
• History of clinically significant uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases
• Clinically significant neoplastic disease
• Excessive use of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [354 mL], wine [118 mL], or distilled spirits [29.5 mL]) per day
• Current regular user (including use of any illicit drugs) or history of drug (including alcohol) abuse within the last 3 months
• Surgery, donation of 1 unit of blood (approximately 500 mL) or participation in another investigational study within a period of 4 weeks prior to the screening visit
• History of multiple and/or severe allergies, or anaphylactic reaction or intolerability to prescription or nonprescription drugs or food
• Pregnant or lactating
• Expecting to donate eggs or sperm